The Gene?Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
2026-02-20 10:01:00 ET
Vertex Pharmaceuticals ' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP) , is the real buy for long-term investors.
Shares of Vertex, a biotech based in Boston, popped last week after it reported its fourth-quarter results, which included higher 2025 sales for Casgevy, a gene-editing therapy for two genetic blood disorders: sickle cell disease and beta thalassemia. Vertex is already profitable, and makes most of its revenues by selling the only approved drugs for treating cystic fibrosis: Alyftrek, Trikafta, Symdeko, Orkambi, and Kalydeco. The company has also predicted further sales growth for Casgevy this year. Its share price did moderate in the days that followed that report, however, and it gave back most of its short-term gains.
Image source: Getty Images.
NASDAQ: CRSP
CRSP Trading
4.62% G/L:
$57.7992 Last:
499,867 Volume:
$55.59 Open:
